FIELD: biotechnologies.
SUBSTANCE: invention proposes a monoclonal antibody that specifically binds sulphatides and sulphated proteoglycans, as well as a pharmaceutical composition for treatment of atherosclerosis and a set of reagents for diagnostics of atherosclerotic damages, use of an antibody for obtaining a medicinal agent for treatment of atherosclerosis and as a vaccine.
EFFECT: as per the present invention, an antibody has increased reaction capacity in relation to sulphatides and sulphated proteoglycans in comparison to antibody P36.
7 cl, 6 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES FOR ADMINISTERING BIOLOGICALLY ACTIVE COMPOUNDS | 2009 |
|
RU2567667C2 |
| IMMUNOTHERAPEUTIC TREATMENT | 2006 |
|
RU2454428C2 |
| MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2004 |
|
RU2361879C2 |
| ACTIVE ANGIOGENESIS-PREVENTING IMMUNETHERAPY | 2003 |
|
RU2329824C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 |
|
RU2566264C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| METHODS FOR IDENTIFYING AND PREDICTING RISK OF CARDIOVASCULAR EVENT OR DISEASE OR FATAL OUTCOME, METHODS FOR ASSESSING SEVERITY AND MONITORING OF CARDIOVASCULAR EVENT OR DISEASE, METHOD FOR MONITORING EFFECTIVENESS OF THERAPY | 2014 |
|
RU2721690C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| RECOMBINANT CHIMERIC PROTEIN ANTH1, NUCLEIC ACID ENCODING ITS AND THEIR USING | 2003 |
|
RU2322455C2 |
